Cancer Genetics Inc., a Rutherford-based maker of genomic-based oncology tests, is launching a proprietary test for cervical cancer, the second-most common cancer among women worldwide.
The company plans to market the product globally through its network of distribution partners. Cancer Genetics says its test uses a unique combination of genetic markers to detect genetic abnormalities.
The company estimates about 500,000 new cases of cervical cancer occur annually, with about 80 percent coming from developing countries. CGI plans to conduct workshops in India and Mexico to accelerate adoption of its test among clinicians.
“We think that FHACT will be a new tool to help identify women with high risk of progressing to cervical cancer,” Dr. Q. Annie Hasan, a department head at Kamineni Hospitals in India, said in a statement. “This is particularly important in India due to rising incidence of cervical cancer caused by difficulty in implementation of cervical screening programs, which require repeated evaluation in large number of woman.”
By identifying lesions that will progress to a higher grade, the company says the test can allow for better treatment of patients before referral for colposcopy and reduce the overall health care burden.
Cancer Genetics says the test can be performed directly on Pap smear or liquid-based cytology and does not require resampling, making it an ideal fit where women have reduced access to health screening.
In addition cervical cancer, Cancer Genetics said this test is applicable to other HPV-associated cancers. The company is also conducting studies regarding head, neck and anal cancer, the results of which are expected by year’s end.
Cancer Genetics completed an initial public offering in April, raising about $6.9 million. It reported $1.2 million revenue in the first quarter after posting annual revenue of $4.3 million in 2012.
Reporter Tom Zanki is @BizTZanki on Twitter.